ଭେକୁରୋନିଅମ ବ୍ରୋମାଇଡ

ଭେକୁରୋନିଅମ ବ୍ରୋମାଇଡ
Clinical data
AHFS/Drugs.com	monograph
Pregnancy; category	US: C (Risk not ruled out) ; ;
Routes of; administration	Intravenous
ATC code	M03AC03 (WHO) ;
Legal status
Legal status	US: ℞-only ;
Pharmacokinetic data
Bioavailability	100% (IV)
Metabolism	liver 30%
Onset of action	< 1 min
Elimination half-life	51–80 minutes (longer with renal failure)
Duration of action	15 - 30 min
Excretion	Fecal (40-75%) and kidney (30% as unchanged drug and metabolites)
Identifiers
	IUPAC name [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17S)-17-Acetyloxy-10,13-dimethyl-16-(1-methyl-3,4,5,6-tetrahydro-2H-pyridin-1-yl)-2-(1-piperidyl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate bromide;
CAS Number	50700-72-6 ;
PubChem CID	39764;
ChemSpider	36357 ;
UNII	7E4PHP5N1D;
ChEMBL	CHEMBL1201219 ;
ECHA InfoCard	100.051.549
Chemical and physical data
Formula	C34H57BrN2O4
Molar mass	637.73 g/mol
3D model (JSmol)	Interactive image;
	SMILES CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CCCCC4)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C.[Br-];
	InChI InChI=1S/C34H57N2O4.BrH/c1-23(37)39-31-20-25-12-13-26-27(34(25,4)22-29(31)35-16-8-6-9-17-35)14-15-33(3)28(26)21-30(32(33)40-24(2)38)36(5)18-10-7-11-19-36;/h25-32H,6-22H2,1-5H3;1H/q+1;/p-1/t25-,26+,27-,28-,29-,30-,31-,32-,33-,34-;/m0./s1 ; Key:VEPSYABRBFXYIB-PWXDFCLTSA-M ;
(what is this?) (verify)

ଭେକୁରୋନିଅମ ବ୍ରୋମାଇଡ (ଇଂରାଜୀ ଭାଷାରେ Vecuronium bromide, ବିକ୍ରୟ ନାମ ନରକ୍ୟୁରନ/Norcuron) ଏକ ଔଷଧ ଯାହା ମେକାନିକାଲ ଭେଣ୍ଟିଲେସନ (mechanical ventilation) ଓ ଅପରେଶନ ସମୟରେ କଙ୍କାଳୀୟ ମାଂସପେଶୀର ଶିଥିଳତା (skeletal muscle relaxation) ଆଣିବା ନିମନ୍ତେ ଶାରୀରିକ ନିଶ୍ଚେତନ (general anesthesia) ସମୟରେ ଦିଆଯାଏ । ଏଣ୍ଡୋଟ୍ରାକିଆଲ ଇନଟ୍ୟୁବେସନ କରିବା ପୂର୍ବରୁ ଏହା ଦିଆଯାଇପାରେ କିନ୍ତୁ ଅତି ଶୀଘ୍ର ଆବଶ୍ୟକତା ଥିଲେ ସକ୍ସାମେଥୋନିଅମ ଅଧିକ ପସନ୍ଦ‌ଯୋଗ୍ୟ । ଏହା ଶିରାଭ୍ୟନ୍ତରରେ ଇଞ୍ଜେକସନ (injection into a vein) ଆକାରରେ ଦିଆଯାଏ । ଚାରି ମିନିଟ ମଧ୍ୟରେ ଏହାର ପ୍ରଭାବ ଆରମ୍ଭ ହୋଇ ପ୍ରାୟ ଏକ ଘଣ୍ଟା ପର୍ଯ୍ୟନ୍ତ ରହେ ।^[୧]

ଭେକୁରୋନିଅମ ବ୍ରୋମାଇଡର ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନିମ୍ନ ରକ୍ତଚାପ (low blood pressure) ଓ ଦୀର୍ଘକାଳୀନ ପକ୍ଷାଘାତ (paralysis) ହୋଇପାରେ ।^[୩] ଏହାର ଆଲର୍ଜି (Allergic reactions) କ୍ୱଚିତ୍ ହୁଏ ।^[୪]ଗର୍ଭାବସ୍ଥାରେ ଶିଶୁପ୍ରତି ଏହାର ନିରାପତ୍ତା ବିଷୟ ସ୍ପଷ୍ଟ ହୋଇନାହିଁ । ଏହା ନନ୍‌-ଡିପୋଲାରାଇଜିଙ୍ଗ (non-depolarizing) ଟାଇପର ନିଉରୋମସ୍କୁଲାର ବ୍ଲକର (neuromuscular-blocker) ଔଷଧ । କଙ୍କାଳୀୟ ମାଂସପେଶୀ (skeletal muscles) ଉପରେ ଆସେଟାଇଲକୋଲିନର (acetylcholine) ପ୍ରଭାବକୁ ଅବରୋଧ କରିଦିଏ ।^[୧]

ସନ ୧୯୮୪ରେ ଭେକୁରୋନିଅମ ଡାକ୍ତରୀ ବ୍ୟବ‌ହାର ନିମନ୍ତେ ସ୍ୱୀକୃତ ହୋଇଥିଲା ।^[୧] ଏହାର ନାମ ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନର ଅତ୍ୟାବଶ୍ୟକୀୟ ଔଷଧ ଚିଠାରେ (World Health Organization's List of Essential Medicines) ଅଛି ଯାହା ମୌଳିକ ସ୍ୱାସ୍ଥ୍ୟ ସିସ୍ଟମ (health system) ନିମନ୍ତେ ଅତି ମହତ୍ତ୍ୱପୂର୍ଣ୍ଣ ।^[୫] ଭେକୁରୋନିଅମ ଜେନେରିକ ନାମରେ (generic medication) ବିକ୍ରୟ ହୁଏ ।^[୧] ଯୁକ୍ତରାଷ୍ଟ୍ର ଆମେରିକାରେ ଏହାର ଏକ ଡୋଜର ମୂଲ୍ୟ ୨୫ ଆମେରିକୀୟ ଡଲାରରୁ କମ୍ ।^[୨] ଏହାର ପ୍ରଭାବକୁ ପ୍ରତ୍ୟାବର୍ତ୍ତନ କରିବା ନିମନ୍ତେ ନିଓସ୍ଟିଗମିନ (neostigmine) ଓ ଆଟ୍ରୋପିନ ଆବଶ୍ୟକ ହୁଏ ।^[୧]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ "Vecuronium Bromide". The American Society of Health-System Pharmacists. Retrieved 8 December 2016.
↑ ^୨.୦ ^୨.୧ Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 23. ISBN 9781284057560.
↑ "NORCURON 10mg - Summary of Product Characteristics (SPC) - (eMC)". www.medicines.org.uk. 4 August 2000. Archived from the original on 20 December 2016. Retrieved 16 December 2016.
↑ WHO Model Formulary 2008 (PDF). World Health Organization. 2009. p. 431. ISBN 9789241547659. Retrieved 8 December 2016.
↑ "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Retrieved 8 December 2016.

[AHFS2016-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ "Vecuronium Bromide". The American Society of Health-System Pharmacists. Retrieved 8 December 2016.

[Ric2015-2] ୨.୦ ^୨.୧ Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 23. ISBN 9781284057560.

[3] "NORCURON 10mg - Summary of Product Characteristics (SPC) - (eMC)". www.medicines.org.uk. 4 August 2000. Archived from the original on 20 December 2016. Retrieved 16 December 2016.

[WHO2008-4] WHO Model Formulary 2008 (PDF). World Health Organization. 2009. p. 431. ISBN 9789241547659. Retrieved 8 December 2016.

[WHO19th-5] "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Retrieved 8 December 2016.

[୧]

[୨]

[୩]

[୪]

[୫]

Clinical data

AHFS/Drugs.com	monograph
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	Intravenous
ATC code	M03AC03 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	100% (IV)
Metabolism	liver 30%
Onset of action	< 1 min^[୧]
Elimination half-life	51–80 minutes (longer with renal failure)
Duration of action	15 - 30 min^[୨]
Excretion	Fecal (40-75%) and kidney (30% as unchanged drug and metabolites)
Identifiers
IUPAC name [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17S)-17-Acetyloxy-10,13-dimethyl-16-(1-methyl-3,4,5,6-tetrahydro-2H-pyridin-1-yl)-2-(1-piperidyl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate bromide
CAS Number	50700-72-6^Y
PubChem CID	39764
ChemSpider	36357^N
UNII	7E4PHP5N1D
ChEMBL	CHEMBL1201219^N
ECHA InfoCard	100.051.549
Chemical and physical data
Formula	C₃₄H₅₇BrN₂O₄
Molar mass	637.73 g/mol
3D model (JSmol)	Interactive image
SMILES CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CCCCC4)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C.[Br-]
InChI InChI=1S/C34H57N2O4.BrH/c1-23(37)39-31-20-25-12-13-26-27(34(25,4)22-29(31)35-16-8-6-9-17-35)14-15-33(3)28(26)21-30(32(33)40-24(2)38)36(5)18-10-7-11-19-36;/h25-32H,6-22H2,1-5H3;1H/q+1;/p-1/t25-,26+,27-,28-,29-,30-,31-,32-,33-,34-;/m0./s1^N Key:VEPSYABRBFXYIB-PWXDFCLTSA-M^N
^NY (what is this?) (verify)